Lipoprotein Apheresis in Refractory Angina Study

Status Completed

Clinical Trial Summary

The goal of this study is to determine the impact of apheresis on clinical parameters and symptoms of patients with refractory angina and raised Lp(a). The investigators will conduct a prospective, randomised controlled crossover study of 20 patients with refractory angina and raised Lp(a), randomised to undergoing lipoprotein apheresis weekly for three months or sham apheresis weekly for three months with assessment of myocardial perfusion, carotid atherosclerosis, endothelial vascular function, thrombogenesis, exercise capacity, angina symptoms and quality of life at the beginning and end of treatment. Patients will then crossover to the opposite study arm with the protocol repeated. The hypothesis is that the above parameters will be improved by lipoprotein apheresis in patients with raised Lp(a) and Refractory Angina. Investigators will also test for the genotypic presence of apolipoprotein(a) gene (LPA) locus variants (rs10455872 and rs3798220) which are thought to be associated with an increased level of Lp(a) and an increased risk of coronary disease.

Clinical Trial Description

Angina which is refractory to conventional medical therapy and revascularisation is challenging to manage. Lipoprotein(a) or Lp(a) is a genetically determined form of LDL-cholesterol, elevation of which is an independent risk factor and predictor of adverse cardiovascular events. Lp(a) is felt to increase cardiovascular risk via its prothrombotic effect and by enhancing intimal lipoprotein deposition. Lipoprotein apheresis is the most effective treatment for raised Lp(a). Lipid lowering agents such as statins have little to no effect on Lp(a) levels. ;

Study Design

Related Conditions & MeSH terms

Angina Pectoris
Raised Lipoprotein(a)>50mg/dL or >500mg/L
Refractory Angina

Clinical Trial Details

NCT number	NCT01796912
Study type	Interventional
Source	Imperial College London
Contact
Status	Completed
Phase	N/A
Start date	February 2013
Completion date	November 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01205893` - Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA	Phase 2
Suspended	`NCT04306237` - A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina	Phase 2
Recruiting	`NCT04892537` - Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance	N/A
Completed	`NCT00694642` - Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis	Phase 1/Phase 2
Suspended	`NCT00820586` - Intramyocardial Delivery of Autologous Bone Marrow	Phase 2
Recruiting	`NCT04368819` - Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms	Phase 2/Phase 3
Recruiting	`NCT05711849` - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina	Phase 2
Recruiting	`NCT03455725` - CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial	N/A
Completed	`NCT01966042` - Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina	Phase 2
Recruiting	`NCT03991871` - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study	N/A
Recruiting	`NCT05102019` - Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II	N/A
Completed	`NCT03218891` - Cardiac Rehabilitation in Patients With Refractory Angina	N/A
Completed	`NCT03350737` - Coronary Arteriogenetic Heparinized Exercise	N/A
Recruiting	`NCT01566175` - Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization	N/A
Recruiting	`NCT05492110` - Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.	N/A
Recruiting	`NCT04606459` - COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina	N/A